Michael King
Stock Analyst at Rodman & Renshaw
(1.25)
# 3,660
Out of 5,172 analysts
110
Total ratings
37.07%
Success rate
-9.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $17 | $1.51 | +1,025.83% | 1 | Mar 17, 2026 | |
| KPTI Karyopharm Therapeutics | Initiates: Buy | $28 | $7.63 | +266.97% | 1 | Mar 10, 2026 | |
| ELTX Elicio Therapeutics | Initiates: Buy | $17 | $10.85 | +56.68% | 1 | Mar 10, 2026 | |
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $18.49 | +3,415.41% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $2.13 | +416.43% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.14 | +2,707.02% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.23 | +5,469.11% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $11.30 | +1,669.91% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.79 | +955.98% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $732.87 | +17.62% | 11 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $41.27 | -41.85% | 10 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $166 | $3.71 | +4,374.39% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $12.13 | +246.25% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $312.17 | -2.62% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $12.84 | +803.43% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.15 | +100.00% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $44.64 | -46.24% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $62.37 | -26.24% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $27.86 | +244.58% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $504 | $7.86 | +6,312.21% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $33.38 | -7.13% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $663.93 | -94.58% | 2 | Nov 13, 2017 |
BioXcel Therapeutics
Mar 17, 2026
Initiates: Buy
Price Target: $17
Current: $1.51
Upside: +1,025.83%
Karyopharm Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $28
Current: $7.63
Upside: +266.97%
Elicio Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $17
Current: $10.85
Upside: +56.68%
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $18.49
Upside: +3,415.41%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $2.13
Upside: +416.43%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.14
Upside: +2,707.02%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.23
Upside: +5,469.11%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $11.30
Upside: +1,669.91%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.79
Upside: +955.98%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $732.87
Upside: +17.62%
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $41.27
Upside: -41.85%
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.71
Upside: +4,374.39%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $12.13
Upside: +246.25%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $312.17
Upside: -2.62%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $12.84
Upside: +803.43%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.15
Upside: +100.00%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $44.64
Upside: -46.24%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $62.37
Upside: -26.24%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $27.86
Upside: +244.58%
Jan 10, 2022
Initiates: Buy
Price Target: $504
Current: $7.86
Upside: +6,312.21%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $33.38
Upside: -7.13%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $663.93
Upside: -94.58%